Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma
Adding the bispecific antibody epcoritamab to rituximab and lenalidomide (R2) provides great overall responses in patients with high-risk follicular lymphoma. This is one of the conclusions that MD and PhD, Anna Sureda Balari, presented at this year’s EHA 2023 congress. Let her elaborate on her findings in this MEDtalk.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in